Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:FLGT NASDAQ:QIPT NASDAQ:TOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$21.12$21.74$14.59▼$44.28$640.57M1.04328,041 shs726,610 shsFLGTFulgent Genetics$17.96-0.2%$16.80$13.46▼$31.04$511.21M0.94443,369 shs684,421 shsQIPTQuipt Home Medical$3.65$3.62$1.35▼$3.65$162.30M0.54676,348 shsN/ATOIOncology Institute$5.26$4.19$2.02▼$5.57$519.89M0.371.75 million shs2.14 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences0.00%+2.03%+5.44%-15.52%+11.69%FLGTFulgent Genetics0.00%-3.85%+9.45%+15.70%-11.53%QIPTQuipt Home Medical0.00%0.00%0.00%0.00%+102.78%TOIOncology Institute0.00%-0.94%+25.24%+58.43%+121.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$21.12$21.74$14.59▼$44.28$640.57M1.04328,041 shs726,610 shsFLGTFulgent Genetics$17.96-0.2%$16.80$13.46▼$31.04$511.21M0.94443,369 shs684,421 shsQIPTQuipt Home Medical$3.65$3.62$1.35▼$3.65$162.30M0.54676,348 shsN/ATOIOncology Institute$5.26$4.19$2.02▼$5.57$519.89M0.371.75 million shs2.14 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences0.00%+2.03%+5.44%-15.52%+11.69%FLGTFulgent Genetics0.00%-3.85%+9.45%+15.70%-11.53%QIPTQuipt Home Medical0.00%0.00%0.00%0.00%+102.78%TOIOncology Institute0.00%-0.94%+25.24%+58.43%+121.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 2.67Moderate Buy$42.83102.81% UpsideFLGTFulgent Genetics 2.20Hold$27.0050.33% UpsideQIPTQuipt Home Medical 1.75Reduce$3.65N/ATOIOncology Institute 2.60Moderate Buy$7.7547.34% UpsideCurrent Analyst Ratings BreakdownLatest QIPT, CSTL, FLGT, and TOI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026TOIOncology Institute Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $7.006/8/2026TOIOncology Institute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.006/1/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026CSTLCastle Biosciences KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/26/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026CSTLCastle Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.005/7/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/7/2026CSTLCastle Biosciences Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $43.005/5/2026FLGTFulgent Genetics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$30.00 ➝ $15.004/27/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/20/2026TOIOncology Institute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$339.92M1.88$1.11 per share18.97$16.13 per share1.31FLGTFulgent Genetics$322.67M1.58N/AN/A$35.80 per share0.50QIPTQuipt Home Medical$264.97M0.61$0.95 per share3.85$2.58 per share1.41TOIOncology Institute$502.73M1.03N/AN/A($0.16) per share-32.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%8/3/2026 (Estimated)FLGTFulgent Genetics-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)QIPTQuipt Home Medical-$10.70M-$0.24N/AN/AN/A-4.05%-9.94%-4.10%N/ATOIOncology Institute-$60.61M-$0.37N/AN/AN/A-7.42%N/A-24.68%8/12/2026 (Estimated)Latest QIPT, CSTL, FLGT, and TOI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TOIOncology Institute-$0.07-$0.02+$0.05-$0.02$142.10 million$147.44 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/AQIPTQuipt Home MedicalN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.026.756.53FLGTFulgent GeneticsN/A5.315.31QIPTQuipt Home Medical0.811.040.68TOIOncology InstituteN/A1.471.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%FLGTFulgent Genetics48.06%QIPTQuipt Home Medical42.85%TOIOncology Institute36.86%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.10%FLGTFulgent Genetics36.18%QIPTQuipt Home Medical13.40%TOIOncology Institute4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54030.33 million28.48 millionOptionableFLGTFulgent Genetics1,31528.40 million18.13 millionOptionableQIPTQuipt Home Medical1,60044.47 million38.51 millionOptionableTOIOncology Institute66098.84 million94.49 millionNot OptionableQIPT, CSTL, FLGT, and TOI HeadlinesRecent News About These CompaniesThe Oncology Institute, Inc. $TOI Shares Bought by Josh Arnold Investment Consultant LLCJune 19 at 5:03 AM | marketbeat.comYale Podnos Sells 23,451 Shares of Oncology Institute (NASDAQ:TOI) StockJune 10, 2026 | insidertrades.comHow Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%June 9, 2026 | zacks.comJorey Chernett Buys 12,000 Shares of Oncology Institute (NASDAQ:TOI) StockJune 6, 2026 | insidertrades.comOncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Acquires 12,000 SharesJune 5, 2026 | marketbeat.comTopicus.com Inc. Announces a Revised Proposal to Acquire ReadyTechMay 31, 2026 | globenewswire.comThe Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring ConferenceMay 26, 2026 | globenewswire.comGatePass Capital LLC Invests $1.28 Million in The Oncology Institute, Inc. $TOIMay 26, 2026 | marketbeat.comTiff Advisory Services LLC Reduces Position in The Oncology Institute, Inc. $TOIMay 24, 2026 | marketbeat.comOncology Institute (NASDAQ:TOI) Major Shareholder Purchases $20,250.00 in StockMay 22, 2026 | insidertrades.comOncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Buys 5,000 SharesMay 21, 2026 | marketbeat.comJorey Chernett Buys 33,500 Shares of Oncology Institute (NASDAQ:TOI) StockMay 21, 2026 | marketbeat.comOncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Purchases 30,000 SharesMay 21, 2026 | insidertrades.comNeedham Keeps Their Buy Rating on Oncology Institute (TOI)May 17, 2026 | theglobeandmail.comThe Oncology Institute to Participate in B. Riley Securities Institutional Investor ConferenceMay 13, 2026 | globenewswire.comThe Oncology Institute, Inc. (NASDAQ:TOI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.00May 11, 2026 | finance.yahoo.comThe Oncology Institute, Inc. (TOI) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comThe Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue EstimatesMay 7, 2026 | zacks.comThe Oncology Institute Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comWhat To Expect From The Oncology Institute Inc (TOI) Q1 2026 EarningsMay 6, 2026 | finance.yahoo.comConstellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026May 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQIPT, CSTL, FLGT, and TOI Company DescriptionsCastle Biosciences NASDAQ:CSTL$21.12 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$21.08 -0.04 (-0.19%) As of 06/18/2026 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Fulgent Genetics NASDAQ:FLGT$17.96 -0.04 (-0.22%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$18.00 +0.04 (+0.19%) As of 06/18/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Quipt Home Medical NASDAQ:QIPTQuipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.Oncology Institute NASDAQ:TOI$5.26 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$5.26 0.00 (-0.10%) As of 06/18/2026 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
